Overview

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
To assess patient preference between ODM-201 and enzalutamide by patient preference questionnaire
Phase:
Phase 2
Details
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris